We found that MTA1 overexpression in breast tumors (n = 37) associates (P = 0.024540) with a poor disease-specific survival (HR[95% CI] = 1.54[0.89–2.64]) of breast cancer patients (n = 37). This evidence concerns the gene MTA1 and breast carcinoma.